AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Journal of Neurorestoratology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Integrative insights into cerebrometabolic disease: Understanding, management, and future prospects

Gaili Yana, Xiangyu Zhanga,b, Yang Liua,b, Pingping Guoa,b, Yuanyuan Liua, Xin Lia, V. Wee Yongc( ), Mengzhou Xuea,b( )
Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, Henan, China
Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China
Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary T2N 1N4, Alberta, Canada
Show Author Information

Abstract

Cerebrovascular disease is among the most common causes of permanent disability and mortality in adults and places immense pressure on health care resources. Metabolic diseases caused by susceptibility genes and unhealthy lifestyle play a key role in the development of cerebrovascular disease. Cardiometabolic disease is now well established and rapidly evolving. Cardiometabolic medicine, which considers metabolic issues and cardiovascular disease as an integrated whole, has been implemented in many countries worldwide. However, integrated management of metabolic risk factors and cerebrovascular disease is still in the initial stages. In this minireview, we propose a concept and definition of cerebrometabolic disease, describe its possible pathogenesis, summarize the recently proposed integrative therapeutic approach, and discuss future developments as well as challenges, with the aim of promoting a deeper understanding and integrated management of metabolic issues and cerebrovascular disease.

Keywords

Cerebrovascular diseaseMetabolic disordersPioglitazoneCerebrometabolic diseaseSodium–glucose cotransporter-2Glucagon-like peptide-1

References

1

Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395(10226): 785–794. https://doi.org/10.1016/S0140-6736(19)32007-0.
Crossref Google Scholar
2

Sidney S, Quesenberry Jr CP, Jaffe MG, et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. 2016;1(5): 594–599. https://doi.org/10.1001/jamacardio.2016.1326.
Crossref Google Scholar
3

Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. Int J Epidemiol. 2019;48(6):1815–1823. https://doi.org/10.1093/ije/dyz143.
Crossref Google Scholar
4

Saxon DR, Reiter-Brennan C, Blaha MJ, et al. Cardiometabolic medicine: development of a new subspecialty. J Clin Endocrinol Metab. 2020;105(7): dgaa261. https://doi.org/10.1210/clinem/dgaa261.
Crossref Google Scholar
5

Mechanick JI, Farkouh ME, Newman JD, et al. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(5):539–555. https://doi.org/10.1016/j.jacc.2019.11.046.
Crossref Google Scholar
6

Mechanick JI, Farkouh ME, Newman JD, et al. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(5):525–538. https://doi.org/10.1016/j.jacc.2019.11.044.
Crossref Google Scholar
7

Xu J, Wang YJ. Cerebro-metabolic disease: concept, method, challenge and future directions. Chinese J. Stroke. 2023;18:617–627. https://doi.org/10.3969/j.issn.1673-5765.2023.06.001.
Crossref Google Scholar
8

Zhang XY, Khan S, Wei RX, et al. Application of nanomaterials in the treatment of intracerebral hemorrhage. J Tissue Eng. 2023;14:20417314231157004. https://doi.org/10.1177/20417314231157004.
Crossref Google Scholar
9

Huang HY, Chen L, Sanberg PR, et al. Beijing declaration of international as-sociation of neurorestoratology (2023 Xi’an version). J Neurorestoratol. 2023;11(2):100055. https://doi.org/10.1016/j.jnrt.2023.100055.
Crossref Google Scholar
10

Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet. 2010;375(9710):181–183. https://doi.org/10.1016/s0140-6736(09)61794-3.
Crossref Google Scholar
11

Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syn-drome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation. 2004;109(1):42–46. https://doi.org/10.1161/01.CIR.0000108926.04022.0C.
Crossref Google Scholar
12

Laclaustra M, Moreno-Franco B, Lou-Bonafonte JM, et al. Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome. Dia-betes Care. 2019;42(2):303–310. https://doi.org/10.2337/dc18-1410.
Crossref Google Scholar
13

Penna GC, Bianco AC, Ettleson MD. A cross-sectional analysis of cardiovascular and bone healthcare utilization during treatment with thyroid hormone. J Clin Endocrinol. 2023;109(3):e1143–e1150. https://doi.org/10.1210/clinem/dgad629.
Crossref Google Scholar
14

Wong SK, Chin KY, Suhaimi FH, et al. The relationship between metabolic syndrome and osteoporosis: a review. Nutrients. 2016;8(6):347. https://doi.org/10.3390/nu8060347.
Crossref Google Scholar
15

Richter-Stretton GL, Fenning AS, Vella RK. Skeletal muscle - a bystander or influencer of metabolic syndrome? Diabetes Metabol Syndr. 2020;14(5): 867–875. https://doi.org/10.1016/j.dsx.2020.06.006.
Crossref Google Scholar
16

Ng CH, Huang DQ, Nguyen MH. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: prevalence, outcomes and implica-tions of a change in Name. Clin Mol Hepatol. 2022;28(4):790–801. https://doi.org/10.3350/cmh.2022.0070.
Crossref Google Scholar
17

Zhang RY, Dong YF, Liu Y, et al. Enhanced liver X receptor signalling reduces brain injury and promotes tissue regeneration following experimental intra-cerebral haemorrhage: roles of microglia/macrophages. Stroke Vasc Neurol. 2023;8(6):486–502. https://doi.org/10.1136/svn-2023-002331.
Crossref Google Scholar
18

Ogdie A, Yu YD, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–332. https://doi.org/10.1136/annrheumdis-2014-205675.
Crossref Google Scholar
19

Ahlehoff O, Gislason GH, Jørgensen CH, et al. Psoriasis and risk of atrial fibril-lation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012;33(16):2054–2064. https://doi.org/10.1093/eurheartj/ehr285.
Crossref Google Scholar
20

Meissner Y, Richter A, Manger B, et al. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis. 2017;76(9):1583–1590. https://doi.org/10.1136/annr-heumdis-2017-211209.
Crossref Google Scholar
21

Lindhardsen J, Ahlehoff O, Gislason GH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ. 2012;344:e1257. https://doi.org/10.1136/bmj.e1257.
Crossref Google Scholar
22

Arkema EV, Svenungsson E, Von Euler M, et al. Stroke in systemic lupus ery-thematosus: a Swedish population-based cohort study. Ann Rheum Dis. 2017;76(9):1544–1549. https://doi.org/10.1136/annrheumdis-2016-210973.
Crossref Google Scholar
23

Singh S, Kullo IJ, Pardi DS, et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12(1): 26–35. https://doi.org/10.1038/nrgastro.2014.202.
Crossref Google Scholar
24

Dregan A, Charlton J, Chowienczyk P, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130(10):837–844. https://doi.org/10.1161/CIRCULATIONAHA.114.009990.
Crossref Google Scholar
25

Kuo HK, Yen CJ, Chang CH, et al. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic re-view and meta-analysis. Lancet Neurol. 2005;4(6):371–380. https://doi.org/10.1016/S1474-4422(05)70099-5.
Crossref Google Scholar
26

Xue MZ, Yong VW. Neuroinflammation in intracerebral haemorrhage: immu-notherapies with potential for translation. Lancet Neurol. 2020;19(12): 1023–1032. https://doi.org/10.1016/S1474-4422(20)30364-1.
Crossref Google Scholar
27

Li HM, Ghorbani S, Ling CC, et al. The extracellular matrix as modifier of neuroinflammation and recovery in ischemic stroke and intracerebral hem-orrhage. Neurobiol Dis. 2023;186:106282. https://doi.org/10.1016/j.nbd.2023.106282.
Crossref Google Scholar
28

Xue CX, Chen KY, Gao ZZ, et al. Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction. Cell Commun Signal. 2023;21(1):298. https://doi.org/10.1186/s12964-022-01016-w.
Crossref Google Scholar
29

Guix FX, Uribesalgo I, Coma M, et al. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol. 2005;76(2):126–152. https://doi.org/10.1016/j.pneurobio.2005.06.001.
Crossref Google Scholar
30

Habashy KJ, Ahmad F, Ibeh S, et al. Western and ketogenic diets in neurological disorders: can you tell the difference? Nutr Rev. 2022;80(8):1927–1941. https://doi.org/10.1093/nutrit/nuac008.
Crossref Google Scholar
31

Förstermann U, Xia N, Li HG. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120:713–735. https://doi.org/10.1161/circresaha.116.309326.
Crossref Google Scholar
32

Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res. 2016;118(11):1808–1829. https://doi.org/10.1161/CIRCRESAHA.116.306923.
Crossref Google Scholar
33

Creager MA, Lüscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circula-tion. 2003;108(12):1527–1532. https://doi.org/10.1161/01.CIR.0000091257.27563.32.
Crossref Google Scholar
34

Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017;70(4):660–667. https://doi.org/10.1161/HYPERTENSIONAHA.117.07802.
Crossref Google Scholar
35

Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care. 2007;30(12): 3131–3140. https://doi.org/10.2337/dc06-1537.
Crossref Google Scholar
36

Jensen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation 2014. 2013;129(25 suppl 2):S102–S138. https://doi.org/10.1161/01.cir.0000437739.71477.ee.
Crossref Google Scholar
37

Chen GC, Neelakantan N, Martín-Calvo N, et al. Adherence to the Mediterra-nean diet and risk of stroke and stroke subtypes. Eur J Epidemiol. 2019;34(4): 337–349. https://doi.org/10.1007/s10654-019-00504-7.
Crossref Google Scholar
38

Xie ZB, Sun YN, Ye YQ, et al. Randomized controlled trial for time-restricted eating in healthy volunteers without obesity. Nat Commun. 2022;13(1):1003. https://doi.org/10.1038/s41467-022-28662-5.
Crossref Google Scholar
39

Varady KA, Cienfuegos S, Ezpeleta M, et al. Clinical application of intermittent fasting for weight loss: progress and future directions. Nat Rev Endocrinol. 2022;18(5):309–321. https://doi.org/10.1038/s41574-022-00638-x.
Crossref Google Scholar
40

Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531. https://doi.org/10.1210/er.2010-0029.
Crossref Google Scholar
41

Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42(4):693–700. https://doi.org/10.2337/dc18-2207.
Crossref Google Scholar
42

Kario K, Okada K, Kato M, et al. Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2019;139(18):2089–2097. https://doi.org/10.1161/CIRCULATIONAHA.118.037076.
Crossref Google Scholar
43

Hussain M, Elahi A, Hussain A, et al. Sodium-glucose cotransporter-2 (SGLT-2) attenuates serum uric acid (SUA) level in patients with type 2 diabetes. J Diabetes Res. 2021;2021:9973862. https://doi.org/10.1155/2021/9973862.
Crossref Google Scholar
44

Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a random-ized controlled trial (E-LIFT trial). Diabetes Care. 2018;41(8):1801–1808. https://doi.org/10.2337/dc18-0165.
Crossref Google Scholar
45

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720.
Crossref Google Scholar
46

Imprialos KP, Boutari C, Stavropoulos K, et al. Stroke paradox with SGLT-2 in-hibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry. 2017;88(3):249–253. https://doi.org/10.1136/jnnp-2016-314704.
Crossref Google Scholar
47

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925.
Crossref Google Scholar
48

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/10.1056/NEJMoa1812389.
Crossref Google Scholar
49

Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–139. https://doi.org/10.1056/NEJMoa2030186.
Crossref Google Scholar
50

Koufakis T, Mustafa OG, Tsimihodimos V, et al. Insights into the results of sotagliflozin cardiovascular outcome trials: is dual inhibition the cherry on the cake of cardiorenal protection? Drugs. 2021;81(12):1365–1371. https://doi.org/10.1007/s40265-021-01559-1.
Crossref Google Scholar
51

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabol. 2018;27(4):740–756. https://doi.org/10.1016/j.cmet.2018.03.001.
Crossref Google Scholar
52

Maida A, Hansotia T, Longuet C, et al. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology. 2009;137(6): 2146–2157. https://doi.org/10.1053/j.gastro.2009.09.004.
Crossref Google Scholar
53

Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulino-tropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tir-zepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metabol. 2020;22(10):1886–1891. https://doi.org/10.1111/dom.14110.
Crossref Google Scholar
54

Huang HY, Chen L, Chopp M, et al. The 2020 yearbook of neurorestoratology. J Neurorestoratol. 2021;9(1):1–12. https://doi.org/10.26599/JNR.2021.9040002.
Crossref Google Scholar
55

Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 Mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705–719. https://doi.org/10.1016/S0140-6736(23)01185-6.
Crossref Google Scholar
56

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141.
Crossref Google Scholar
57

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3.
Crossref Google Scholar
58

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 dia-betes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. https://doi.org/10.1056/NEJMoa1509225.
Crossref Google Scholar
59

Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13): 1228–1239. https://doi.org/10.1056/NEJMoa1612917.
Crossref Google Scholar
60

Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Har-mony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. https://doi.org/10.1016/S0140-6736(18)32261-X.
Crossref Google Scholar
61

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. https://doi.org/10.1056/NEJMoa1603827.
Crossref Google Scholar
62

Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovas-cular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9): 841–851. https://doi.org/10.1056/NEJMoa1901118.
Crossref Google Scholar
63

Buse JB, Bain SC, Mann JFE, et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care. 2020;43(7):1546–1552. https://doi.org/10.2337/dc19-2251.
Crossref Google Scholar
64

Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a rando-mised controlled trial. Lancet. 2005;366(9493):1279–1289. https://doi.org/10.1016/S0140-6736(05)67528-9.
Crossref Google Scholar
65

Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04). Stroke. 2007;38(3):865–873. https://doi.org/10.1161/01.STR.0000257974.06317.49.
Crossref Google Scholar
66

Kernan WN, Viscoli CM, Furie KL. Pioglitazone after ischemic stroke or tran-sient ischemic attack. J Vasc Surg. 2016;64(1):260. https://doi.org/10.1016/j.jvs.2016.05.060.
Crossref Google Scholar
67

Spence JD, Viscoli CM, Inzucchi SE, et al. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol. 2019;76(5):526–535. https://doi.org/10.1001/jamaneurol.2019.0079.
Crossref Google Scholar
Journal of Neurorestoratology
Volume 12 Issue 2,
June 2024
Article number: 100107
DOI: 10.1016/j.jnrt.2024.100107
Cite this article:
Yan G, Zhang X, Liu Y, et al. Integrative insights into cerebrometabolic disease: Understanding, management, and future prospects. Journal of Neurorestoratology, 2024, 12(2): 100107. https://doi.org/10.1016/j.jnrt.2024.100107

192

Views

1

Crossref

1

Web of Science

1

Scopus

Altmetrics
Received: 20 December 2023
Revised: 20 January 2024
Accepted: 24 January 2024
Published: 29 February 2024
© 2024 The Author(s).

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return